Dataset Information

New Insights into the Interaction between Graphene Oxide and Beta-Blockers.

ABSTRACT: As a nano-adsorbent, magnetic graphene oxide (GO/Fe3O4) was synthesized to potentially adsorb propranolol (PRO) from water. The synthetic material was characterized by SEM, TEM, VSM, FTIR, XRD, zeta potential, and XPS. The environmental factors, such as pH, humic acid concentration, PRO concentration, and contact time, were investigated regarding their effect on the adsorption process. The kinetics data fitted the pseudo first-order and second-order kinetics equations. The Langmuir equation, the Freundlich equation, and the Sips equation were used to analyze the adsorption isotherms. Electrostatic attraction, hydrogen bonding, and the π-π interaction all contributed to the adsorption process of PRO onto GO/Fe3O4. The discovery of this study emphasized the feasibility of GO/Fe3O4 removal of PRO and expanded the scope of the application of GO.

SUBMITTER: Deng Y

PROVIDER: S-EPMC6835990 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

New Insights into the Interaction between Graphene Oxide and Beta-Blockers.

Deng Yuehua Y Li Yani Y Nie Wenjie W Gao Xiang X Liu Shentan S Tan Xiaochun X Chen Mingming M Hou Dongzhuang D

Nanomaterials (Basel, Switzerland) 20191009 10

As a nano-adsorbent, magnetic graphene oxide (GO/Fe<sub>3</sub>O<sub>4</sub>) was synthesized to potentially adsorb propranolol (PRO) from water. The synthetic material was characterized by SEM, TEM, VSM, FTIR, XRD, zeta potential, and XPS. The environmental factors, such as pH, humic acid concentration, PRO concentration, and contact time, were investigated regarding their effect on the adsorption process. The kinetics data fitted the pseudo first-order and second-order kinetics equations. The ...[more]

PMID: 31600918

Similar Datasets

Project description:Backgroundβ-Blockers have an uncertain effect in heart failure with a preserved ejection fraction of 50% or higher (heart failure with preserved ejection fraction [HFpEF]).Methods and resultsWe included patients with HFpEF from the Swedish Heart Failure Registry (SwedeHF) enrolled from 2011 through 2018. In a 2:1 propensity-score matched analysis (β-blocker use vs nonuse), we assessed the primary outcome first HF hospitalization, the coprimary outcome cardiovascular (CV) death, and the secondary outcomes of all-cause hospitalization and all-cause death. We performed intention-to-treat and a per-protocol consistency analyses. There were a total of 14,434 patients (median age 79 years, IQR 71-85 years, 51% women); 80% were treated with a β-blocker at baseline. Treated patients were younger and had higher rates of atrial fibrillation and coronary artery disease, and higher N-terminal pro-B-type natriuretic peptide levels. In the 4412:2206 patient matched cohort, at 5 years, 42% (95% CI 40%-44%) vs 44% (95% CI 41%-47%) had a HF admission and 38% (IQR 36%-40%) vs 40% (IQR 36%-42%) died from CV causes. In the intention-to-treat analysis, β-blocker use was not associated with HF admissions (hazard ratio 0.95 [95% CI 0.87-1.05, P = .31]) or CV death (hazard ratio 0.94 [95% CI 0.85-1.03, P = .19]). In the subgroup analyses, men seemed to have a more favorable association between β-blockers and outcomes than did women. There were no associations between β-blocker use and secondary outcomes.ConclusionsIn patients with HFpEF, β-blocker use is common but not associated with changes in HF hospitalization or cardiovascular mortality. In the absence of a strong rational and randomized control trials the case for β-blockers in HFpEF remains inconclusive.Bullet points● The effect of β-blockers with heart failure with preserved ejection fraction of 50% or greater is uncertain.● In a propensity score-matched heart failure with preserved ejection fraction analysis in the SwedeHF registry, β-blockers were not associated with a change in risk for heart failure admissions or cardiovascular deaths.Lay summaryThe optimal treatment for heart failure with a preserved pump function remains unknown. Despite the lack of scientific studies, β-blockers are very commonly used. When matching patients with a similar risk profile in a large heart failure registry, the use of β-blockers for the treatment of heart failure with a preserved pump function was not associated with any changes in heart failure hospital admissions or cardiovascular death.

Dataset Information

New Insights into the Interaction between Graphene Oxide and Beta-Blockers.

Publications

New Insights into the Interaction between Graphene Oxide and Beta-Blockers.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets